GENOMIC TESTING

This review discusses the current state of multicancer early detection tests, the role of machine learning in their development, and their implications for oncology practice and patient care.

ARC101, a potential best-in-class T-cell engager that targets solid tumors expressing CLDN6, is being assessed in a first-in-human trial.

Elacestrant prolonged progression-free survival in patients with pretreated, ER-positive, HER2-negative breast cancer.

A real-world study showed HER2DX guided treatment changes in approximately 48% of HER2-positive breast cancer cases.

Updated ASCO guidelines for pleural mesothelioma refine surgery use, recommend immunotherapy, genetic testing, and improve pathologic classification for personalized care.

Molecular oncology is revolutionizing cancer care by using genetic profiling to tailor personalized treatments, improving efficacy, minimizing adverse events, and paving the way for advanced therapies.

Findings from the CUPISCO study found that molecularly guided therapy is more effective than standard chemotherapy for patients with unfavorable nonsquamous cancer of unknown primary.

As the clinical utility of ctDNA continues to be assessed, it is becoming a valuable tool for various cancer types, including gastrointestinal cancers, blood cancers, and other solid tumors.

Druggable gene aberrations and predictive biomarkers has allowed for the use of next-generation sequencing technologies to grow.

In this episode of Targeted Talks, M. Michele Blackwood, MD, FACS, discusses the current landscape of breast cancer treatment and how personalized medicine with genomic testing is changing the field.

In an interview with Targeted Oncology, Sara Kerr, MD discussed the evolution of genomic testing for patients with cancer and highlighted the program used at Allina Health.

In an interview with Targeted Oncology, David L. Bartlett, MD, discussed the utilization and growing importance of genomic testing in cancer care.

In an interview with Targeted Oncology, Shervin Tabrizi, MD, discussed the development of a 2-part priming strategy aimed at enhancing the sensitivity of liquid biopsies for cancer detection and monitoring.

In an interview with Targeted Oncology, Louise Morrell, MD, discussed the landscape of genetic testing in oncology and the latest advancements in the field.

According to experts, genomic testing is a key tool impacting treatment decisions for physicians treating patients with non–small cell lung cancer.

Bill 1196 / Assembly Bill 1673 aims to improve access to precision medicine for patients with cancer in New York by requiring all state-regulated health plans to cover biomarker testing when it is supported by medical and scientific evidence.

Whole-exome sequencing demonstrated the ability to identify genetic conditions in patients for whom clinical guidelines did not require testing.

At the AACR 2023 Annual Meeting, a presentation revealed that people with colorectal cancer and African ancestry are less likely to be candidates for targeted therapy.

In an interview with Targeted Oncology, John Diaz, MD summarized the ovarian cancer treatment paradigm, and discussed the role of genomic testing and novel targets being explored in the space.

As we identify more targets...there will probably be more and newer, perhaps even better, therapeutics than we have currently, said Dennis J. Slamon, MD.

Florida Cancer Specialists & Research Institute celebrated the addition of genomic testing capabilities at its Next Generation Sequencing laboratory in Fort Myers last week with a ribbon cutting ceremony.

According to experts, routine biomarker testing has become a standard part of care for several common tumor types.

Specific biliary tract cancer clusters have distinct clinical and biologic features which may provide opportunities for therapeutic development.

A tumor genomic profiling program has shown feasibility and clinical impact for pediatric patients who are high-risk de novo and relapsed/refractory.

Allegheny Health Network Cancer Institute will be collaborating with Illumina to evaluate the impact of in-house comprehensive genomic profiling to enhance patient care.